, Tracking Stock Market Picks
Enter Symbol:
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

down 62.91 %

Achillion Pharmaceuticals, Inc. (ACHN) downgraded to Underperform by BofA/Merrill

Posted on: Monday,  Sep 30, 2013  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 09/30/2013. Previously BofA/Merrill rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 09/19/2012.,
when the stock price was $9.33. Since then, Achillion Pharmaceuticals, Inc. has lost 62.92% as of 09/30/2013's recent price of $3.46.
If you would have followed the previous BofA/Merrill's recommendation on ACHN, you would have lost 62.91% of your investment in 376 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/30/2013 8:25 AM Sell
as of 12/13/2013
1 Week up  6.84 %
1 Month down  -16.35 %
3 Months down  -42.94 %
1 YTD down  -47.27 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/19/2012 8:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy